DelveInsight's ALK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient ...
Is Alunbrig Right for Me? Your health care provider will consider what type of lung cancer you have and whether it has spread to help choose the right treatment for you. Alunbrig is used for NSCLC ...
Anaplastic lymphoma kinase (ALK) inhibitors have emerged as promising agents for patients with resectable ALK-positive non–small-cell lung cancer (NSCLC). Whether ensartinib, a second-generation ALK ...
If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...
Previously demonstrated survival benefits of crizotinib (Xalkori, Pfizer Inc.) as an adjuvant treatment for advanced ALK-positive non-small cell lung cancer (ALK+NSCLC) did not extend to the setting ...
On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, was ...
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of ...
The discussion concludes with examination of recent research developments, particularly the CROWN trial's 7-year follow-up data presented at the American Society of Clinical Oncology meeting. Dr.
BERLIN -- Almost half of patients with advanced ALK-positive non-small cell lung cancer (NSCLC) have lived 7 years or longer following initial treatment with the ALK inhibitor alectinib (Alecensa), an ...
The discussion transitions to biomarker testing as an essential component of lung cancer diagnosis, with Dr. Florez emphasizing that diagnosis remains incomplete until molecular characterization is ...
Researchers conducted a clinical trial of a prophylactic peptide vaccine in patients with advanced, ALK-positive NSCLC without progression on standard-of-care TKI therapy. This is a syndicated post ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results